Former California Firefighter Funding Psychedelic Retreats for State Firefighters

A retired firefighter from California is funding psychedelic retreats for firefighters to help address mental disorders they developed while on the job.

Access to psychedelics in the United States is mostly limited to a small number of clinical studies, meaning that the vast majority of people who could benefit from psychedelic-assisted therapy never get the chance to try the treatment. Former Santa Clara County firefighter Angela Graham spent close to two decades as a firefighter, and her on-the-job experiences left her with extreme anxiety, uncontrollable anger and depression.

Although she tried conventional mental-health treatments such as talk therapy, she didn’t get any relief from her symptoms until she tried psychedelic-based treatments. After an acquaintance pointed Graham to a clinic located in Puerta Valla, Mexico, that offered guided psychedelic trips with DMT and psilocybin (magic mushrooms) to alleviate mental-health problems, Graham made the trip south last year to try the treatment.

Graham’s guided psychedelic experiences were so impactful that she cofounded the S.I.R.E.N project with her husband to help other state firefighters receive the treatment that had changed her life. The project funds trips to psychedelic retreats for firefighters in the Bay Area looking for alternative treatments to treat mental health issues. By the end of the year, the S.I.R.E.N project will have sent 15 firefighters, a police officer and a firefighter’s spouse on potentially life-changing psychedelic journeys.

While federal U.S. law classifies psychedelics such as psilocybin and DMT as Schedule I drugs with no medical application, Mexico’s psychedelic policies aren’t as strict. This has allowed the project to send Bay Area first responders to Mexico for psychedelic-assisted therapy; the project has also sent people to a church in Texas that is legally exempted from federal psychedelic policies and is allowed to provide therapeutic psychedelics.

In addition to funding from a secretive tech billionaire whom Graham and her husband wouldn’t name, the couple has also poured their own funds into the S.I.R.E.N project to facilitate the psychedelic retreats. Each trip to a psychedelic resort costs between $2,000 to $5,000.

A recent surge in psychedelic research has revealed that psychedelics may be the key to safely treating several debilitating mental-health disorders and providing patients with long-term relief against their symptoms. This includes conditions such as anxiety, eating disorders,  post-traumatic stress disorder (PTSD) and treatment-resistant depression that often fail to respond to conventional mental health treatments such as talk therapy.

The S.I.R.E.N Project and the work the organization is doing illustrates how important it is for different psychedelic startups such as Compass Pathways PLC (NASDAQ: CMPS) to take their drug-development programs through the clinical trial process so that FDA-approved psychedelic treatments can be locally available for those who need them.

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text “Groovy” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.psychedelicnewswire.com

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.psychedelicnewswire.com/Disclaimer

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
www.psychedelicnewswire.com
415.949.5050 Office
Editor@PsychedelicWire.com

PsychedelicNewsWire is part of the InvestorBrandNetwork.

Vancouver cannabis store avoids penalties after employee sells cannabis to minor

Vancouver cannabis store avoids penalties after employee sells cannabis to minor

A cannabis retailer in BC has avoided penalties after an employee sold edibles to a minor in a sting operation. 

A court has found that the company was not responsible for an employee failing to check the ID of a customer due to an extensive training program in place. While the employee was fired for their oversight, the retailer, Eggs Canna, did not have to face a $7,000 monetary penalty or shut down for seven days. 

Here is the sequence of events: On March 26 of this year, as part of an inspection, two BC Liquor and Cannabis Inspectors entered a cannabis store in Vancouver, including one “minor agent” who was only 18 years old. The age of legal access to cannabis in BC is 19. 

The “minor agent” then asked the employee if she could purchase edibles. The employee then directed the inspector to a display where the 18-year-old inspector selected what court records described as a package of Real Fruit Raspberry Chews containing THC 5mg per unit.

Although the staff member advised the minor agent of a 15 percent discount, they did not ask the minor agent what her age was, nor did the employee ask for any identification from the underage agent.

Once the two inspectors left the store with the purchased edibles, a third inspector entered the store, informed the staff member that he had sold cannabis to a minor, and asked for their Selling It Right certificate, which the staff member provided.

Two days later, on March 28, an inspector issued an electronic notice of non-compliance, which led to the issuance of a Notice of Enforcement Action (NOEA) dated April 4, 2023.

In court, the same inspector confirmed that the Licensee, Eggs Canna, had no history of non-compliance and that the contravention alleged in the NOEA was a first offence within a twelve-month period. Because of this, the Liquor and Cannabis Regulation Branch would be the lowest penalty as set out in Schedule 2 of the Regulation for a contravention of this nature, either a $7,000 fine or a seven-day licence suspension. 

Eggs Canna opted, if found responsible, for a seven-day fine. 

CertiCraft

However, the court found that the owners of Eggs Canna had taken the necessary steps to train their employees to check for IDs as part of a three-day “New Hire Orientation” training program. Eggs Canna’s regional manager also confirmed that the employee who sold cannabis to a minor had been fired following the incident. Eggs Canna also had a policy in place at the time requiring employees to ask for the ID of anyone who appeared to be under the age of 40, and the store’s point of sale system included prompts to ask for ID.

Although the Liquor and Cannabis Regulation Branch argued that Eggs Canna was liable for the employee’s noncompliance, the court ruled otherwise, finding the store had a “strict culture of compliance prohibiting the sale of cannabis to minors.”

The reprsentative for Eggs Canna told the court that she would like to see BC’s regulatory branch more willing to work with industry in a more collaborative manner, using discretion, and not penalizing operators “for missteps as the regulatory framework evolves.”

Eggs Canna has three locations, two in Vancouver and one in Kelowna and is a legacy-era cannabis retailer. 

Featured image of the interior of an Eggs Canna location.


Alternative Products Expo: Innovation and Sustainability

Alternative Products Expo: Innovation and Sustainability

image

Financial analysts, savvy investors, business owners, researchers, and pioneers, are invited to attend Alternative Products Expo to be held at the World Market Center, Las Vegas from September 14-16, 2023. Las Vegas plays host to thousands of esteemed events every year, and there are several reasons for this: state-of-the-art hospitality, top-notch facilities, year-round sunshine, and world-class dining and entertainment options. Featuring one-of-a-kind nightlife, the city never fails to provide a memorable experience for the attendees.

Alternative Products Expo (AltPro Expo) promises to deliver unique networking opportunities for customers and businesses alike. The highly anticipated event has earned a reputation for offering an incredible platform for business owners to showcase their unique and sustainable products. As the countdown for this innovative Expo begins, attendees can expect an unmatched experience packed with actionable insights from the industry leaders.

Exciting Opportunities for Forward-Thinking Businesses

Pioneered by a group of socially responsible entrepreneurs, the Alternative Products Expo is committed to connecting revolutionary businesses with health-conscious customers. The expo will feature a wide range of eco-friendly and innovative products, ranging from plant-based foods, and renewable energy technologies, to sustainable packaging solutions and ethical fashion items. They will witness innovative demos and learn of the latest product launches that will shape a sustainable future and reduce the environmental footprint at a global level.

The AltPro Expo provides customers with a unique opportunity to buy products that contribute to an eco-friendly planet. The organizers will implement sustainable practices throughout the Expo to ensure the targeted audience aligns with their values. Attendees will get a unique opportunity to network with like-minded entrepreneurs and potential investors who will share their passion for innovation. By attending thought-provoking seminars and panel discussions, they will get insights into the latest trends and best practices in the alternative products industry.

To learn more, please visit https://cnw.fm/A8zIE.

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.cannabisnewswire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.cannabisnewswire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

Marijuana recommendation by US health agency hailed as first step to easing weed restrictions

(AP) WASHINGTON — The U.S. Department of Health and Human Services has delivered a recommendation to the Drug Enforcement Administration on marijuana policy, and Senate leaders hailed it Wednesday as a first step toward easing federal restrictions on the drug.

HHS Secretary Xavier Becerra said Wednesday on X, the platform formerly known as Twitter, that the agency has responded to President Joe Biden’s request “to provide a scheduling recommendation for marijuana to the DEA.”

“We’ve worked to ensure that a scientific evaluation be completed and shared expeditiously,” he added.

Senate Majority Leader Chuck Schumer said in a statement that HHS had recommended that marijuana be moved from a Schedule I to a Schedule III controlled substance.

Advertisement

“HHS has done the right thing,” Schumer, D-N.Y., said. “DEA should now follow through on this important step to greatly reduce the harm caused by draconian marijuana laws.”

Rescheduling the drug would reduce or potentially eliminate criminal penalties for possession. Marijuana is currently classified as a Schedule I drug, alongside heroin and LSD.

According to the DEA, Schedule I drugs “have no currently accepted medical use in the United States, a lack of accepted safety for use under medical supervision, and a high potential for abuse.”

Schedule III drugs “have a potential for abuse less than substances in Schedules I or II and abuse may lead to moderate or low physical dependence or high psychological dependence.” They currently include ketamine and some anabolic steroids.

Biden requested the review in October 2022 as he pardoned thousands of Americans convicted of “simple possession” of marijuana under federal law.

Senate Finance Committee Chairman Ron Wyden, D-Ore., issued a statement calling for marijuana to be completely descheduled. “However, the recommendation of HHS to reschedule cannabis as a Schedule III drug is not inconsequential,” he added. “If HHS’s recommendation is ultimately implemented, it will be a historic step for a nation whose cannabis policies have been out of touch with reality.”

Bloomberg News first reported on the HHS recommendation.

In reaction to the Bloomberg report, the nonprofit U.S. Cannabis Council said: “We enthusiastically welcome today’s news. … Rescheduling will have a broad range of benefits, including signaling to the criminal justice system that cannabis is a lower priority and providing a crucial economic lifeline to the cannabis industry.”

Alternative Products Expo: Innovation and Sustainability

420 with CNW — Study Finds Psychosis-Prone Young People Registered Surprising Symptom Improvement After Using Marijuana

image

A team of researchers from several institutions has discovered that cannabis may improve symptoms in teenagers and young adults at risk of developing psychosis. The study contradicts claims that marijuana use can trigger the early onset of psychotic disorder symptoms and shows that cannabis may actually deliver modest cognitive functioning improvements while reducing the use of prescribed medications.

Researchers at the Stanford University School of Medicine, Zucker Hillside Hospital, University of California at Davis and the University of Michigan published their findings in the “Psychiatry Research” journal. The study noted that the recent surge in recreational cannabis use has raised questions regarding the possibility of adult use being a trigger for the onset of psychosis.

However, the study authors note that there is little evidence tying cannabis use and negative health outcomes for people who are predisposed to developing psychosis.

The research team followed 210 patients with a clinical high risk (CHR) of psychosis who took part in an Early Detection and Intervention for the Prevention of Psychosis Program (EDIPPP) for two years. Over the study period, the researchers compared prescription medication use with mental health in people who consumed cannabis regularly and people who didn’t consume cannabis.

Individuals who consumed cannabis continually over the two-year study period did not exhibit an increased psychosis transition rate, study authors say, and cannabis use did not contribute to a decline in clinical symptoms, neurocognition or functioning levels. On the contrary, youth who used cannabis continuously exhibited improved clinical symptoms even as their medication use decreased.

Furthermore, the scientists found that CHR youth who used cannabis regularly over the study period had higher social functioning and neurocognition compared to noncannabis users. The recent study adds to the growing body of scientific literature on cannabis and its potential association with psychosis.

Cannabis legalization opponents have long claimed that cannabis use can trigger schizophrenia, especially now that the market is flooded with increasingly potent THC-infused products. Some medical professionals have also stated that continued exposure to high-THC cannabis may cause psychosis-like symptoms in some consumers.

Studies have found that cannabis-induced psychosis is quite rare, with a Canadian study that analyzed 23,000 consumers finding that only 26 individuals required hospitalization for psychotic-like symptoms. Data from Canada also shows that although the country legalized adult-use cannabis in 2018, there has been no significant increase in the number of emergency room visits due to cannabis-induced schizophrenia or psychosis.

Additionally, a European study published in the “Translation Psychiatry” journal found that less than one-half of 1% of 230,000 consumers experienced psychosis-like symptoms after consuming cannabis.

As the different misconceptions about marijuana are dispelled one at a time, demand for the substance is likely to increase and enterprises such as Advanced Container Technologies Inc. (OTC: ACTX), which capitalize on availing some of the products that marijuana cultivators need, could grow their businesses.

NOTE TO INVESTORS: The latest news and updates relating to Advanced Container Technologies Inc. (OTC: ACTX) are available in the company’s newsroom at https://cnw.fm/ACTX

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

The case for government to help fund cannabis emissions testing

The case for government to help fund cannabis emissions testing

image

Hopefully you’ve seen The Globe and Mail article from August 2 entitled “In the Dark”, which provides a snapshot of where the industry stands regarding cannabis emissions testing. To put it bluntly, the picture is murky. While we have made major headway in the cannabis space, there is still a lot left to do!

The article quotes Anne McLellan, former federal health minister and deputy prime minister who chaired a task force that worked toward legalization. She expressed surprise and disappointment that the government hasn’t funded any research into emissions testing after five years, despite promises to do so during the legalization debate. 

Ken Weisbrod, a licensed pharmacist and medical advisory board leader, echoes her sentiments. 

“We just want to have a conversation about what exactly we are consuming, and for whatever reason that has just not been able to happen,” the article quotes Weisbrod as saying. It’s important to note that advisory board members are not prohibitionists and were among the earliest supporters of legalization. 

Recall, too, Health Canada’s July announcement that it is actively testing legal and illicit cannabis products to provide Canadians with more accurate info about cannabis health and safety risks. 

This adds up to a noticeable desire for more data about what cannabis users are consuming, particularly regarding emissions. 

Does this signal a shift toward more robust regulations, especially concerning emissions?  

Regulatory Insights from the Tobacco Industry

The air is thick with uncertainty, and LPs know what that could mean: escalating costs. And for consumers? A potentially narrower selection in their cannabis choices, driven by a desire for safety and clarity.

The cannabis industry’s embryonic regulatory framework is nothing new; tobacco has undergone a similar journey. Looking back at the landscape of tobacco and nicotine-containing products regulation can provide insight into what we may be able to expect in the cannabis industry. 

Tobacco has faced intense regulatory scrutiny since the 1990s, and there is still more work to be done. “If tobacco is at stage 6 of a regulatory journey, then cannabis is at about stage 2,” said Rana Tayyarah, Senior Director of Commercial Product Development at Labstat. “This means we should be preparing for the evolution of the cannabis industry, driven by potential new regulations and consumer demands for more.” 

Toward A Solution

So, what does that look like for the industry and LPs?

For industry, it could mean more research into cannabis, particularly emissions testing. “Whatever your role in the industry – LP, government, testing lab, scientist – I think we all agree that more data is a good thing,” said Tayyarah. “Consumers increasingly desire as much information as possible about whatever they’re consuming, be it food, beverages, or cannabis.” 

To LPs navigating economic headwinds that have led to the closings of some of their counterparts, this understandably raises concerns about new regulations and higher costs. The last thing the industry needs is a heavier economic burden to bear. 

“For that reason, we think it’s important that the government use money from the taxes and fees it’s collected over the past five years to help fund new research,” said Tayyarah. “Canada is the first G7 country to legalize cannabis, and we have a great opportunity to lead the world in cannabis testing and utilization for medicinal and recreational purposes.” 

Why is Emissions Testing so Challenging? 

Another reason for federal funding into more research is the challenges inherent to studying cannabis, particularly emissions. Most LPs simply don’t have the economic or technical resources to take on this work. 

Some of the challenges of emissions testing include:

  • Costs for laboratory testing equipment, like smoking machines, that can surpass $200,000.
  • Technical expertise to design testing protocols, operate equipment, and interpret results. 
  • The difficulty inherent to burning a combustible product and analyzing the resulting matrix despite the “background noise” from the various by-products. 
  • Lack of regulatory guidance surrounding emissions testing. 

Is the Current Testing Paradigm Overlooking Key Aspects of Consumer Experience?

Regarding emissions regulations (or lack thereof), the Cannabis Act places a great deal of emphasis on the quality of production, providing guidelines on Good Production Practices, including the control of the cultivation, harvesting, and processing environments. 

While important, the current focus has been predominantly on the tangible product – ensuring the flower or liquid concentrate is free from contaminants like heavy metals, pesticides, and pathogens. 

This approach can overlook the final form of the product as experienced by the consumer, be it the smoke from a pre-roll or the emissions from a vape. Current testing paradigms, while rigorous, sidestep the unique compounds created during combustion or vaporization, which can differ from the flower, pre-roll, or other product itself.

Unless Health Canada crafts new regulations, it’s up to LPs and scientists to pioneer work in the area of emissions testing, which requires a major commitment and investment of resources – both of which most LPs cannot spare right now. 

Advancing Cannabis Testing: The Need for Comprehensive Emission Analysis and Industry Collaboration

As the industry develops, it’s essential to stay a step ahead. While most everyone agrees we need more testing, it’s imperative that everyone work together to achieve this goal, including LPs, government, and scientists. 

“Cannabis’ regulatory journey is still unfolding,” said Tayyarah. “But we can see a desire for more testing and analysis, just like with tobacco 30 years ago. At Labstat, we’re focused on helping LPs get the product data they need and that their customers want so they can move the industry forward.”

With an industry-wide commitment to more testing, and help from the government, we can continue to understand cannabis and provide consumers detailed, accurate data so they can make informed decisions.

Content sponsored by: Labstat